Galectin-9: From cell biology to complex disease dynamics

Journal of Biosciences

Volumn 41, Issue 3, 2016, Pages 507-534

  John, Sebastian ^a   Mishra, Rashmi ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

Cancer; carbohydrate recognition domain; galectin 9; immune regulation; linker peptide

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; ECALECTIN; GLYCOCONJUGATE; T CELL IMMUNOGLOBULIN MUCIN DOMAIN 3; UNCLASSIFIED DRUG; GALECTIN; LGALS9 PROTEIN, HUMAN;

CANCER; CARBOHYDRATE; IMMUNE SYSTEM; PEPTIDE; PROTEIN;

ALLERGIC DISEASE; ANTI GLOMERULAR BASEMENT MEMBRANE GLOMERULONEPHRITIS; APOPTOSIS; ASTHMA; AUTOIMMUNE HEPATITIS; BACTERIAL INFECTION; BINDING AFFINITY; BIOCHEMISTRY; BIOGENESIS; C TERMINAL CARBOHYDRATE RECOGNITION DOMAIN; CARTILAGE CELL; CELL ADHESION; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CILIOGENESIS; CYTOLOGY; DIABETIC NEPHROPATHY; DISEASE DYNAMICS; DYNAMICS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GAL 9 GENE; GENE CONTROL; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMAN; IMMUNE THROMBOCYTOPENIA; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LINKER DOMAIN; LIVER ISCHEMIC REPERFUSION INJURY; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; MULTIPLE SCLEROSIS; N TERMINAL CARBOHYDRATE RECOGNITION DOMAIN; NEOPLASM; NEPHRITIS; NEPHROTOXIC SERUM NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OSTEOBLAST; PH; PREGNANCY; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; TUMOR ESCAPE; TUMOR VASCULARIZATION; VIRUS INFECTION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

CELL ADHESION; GALECTINS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84978879674     PISSN: 02505991     EISSN: 09737138     Source Type: Journal    
DOI: 10.1007/s12038-016-9616-y     Document Type: Review

References (161)

1. Alam S, Li H, Margariti A, Martin D, Zampetaki A, Habi O, Cockerill G, Hu Y, et al. 2011 Galectin-9 protein expression in endothelial cells is positively regulated by histone deacetylase 3. J. Biol. Chem. 286 44211–44217
2. Arikawa T, Matsukawa A, Watanabe K, Sakata K-m, Seki M, Nagayama M, Takeshita K, Ito K, et al. 2009 Galectin-9 accelerates transforming growth factor β3-induced differentiation of human mesenchymal stem cells to chondrocytes. Bone. 44 849–857
3. Arikawa T, Saita N, Oomizu S, Ueno M, Matsukawa A, Katoh S, Kojima K, Nagahara K, et al. 2010 Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation. Eur. J. Immunol. 40 548–558
4. Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y, Abedin MJ, Yoshida N, et al. 2002 Selective eosinophil adhesion to fibroblast via IFN- -induced galectin-9. J. Immunol. 169 5912–5918
5. Baba M, Wada J, Eguchi J, Hashimoto I, Okada T, Yasuhara A, Shikata K, Kanwar YS, et al. 2005 Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms. J. Am. Soc. Nephrol. 16 3222–3234
6. Bacigalupo ML, Manzi M, Rabinovich GA and Troncoso MF 2013 Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J. Gastroenterol. 19 8831–8849
7. Baptiste TA, James A, Saria M and Ochieng J 2007 Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin. Exp. Cell Res. 313 652–664
8. Barjon C, Niki T, Verillaud B, Opolon P, Bedossa P, Hirashima M, Blanchin S, Wassef M, et al. 2012 A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses. Infect Agent Cancer 7 16
9. Bauersachs S, Ulbrich SE, Gross K, Schmidt SE, Meyer HH, Wenigerkind H, Vermehren M, Sinowatz F, et al. 2006 Embryo-induced transcriptome changes in bovine endometrium reveal species-specific and common molecular markers of uterine receptivity. Reproduction 132 319–331
10. Bellac CL, Coimbra RS, Simon F, Imboden H and Leib SL 2007 Gene and protein expression of galectin-3 and galectin-9 in experimental pneumococcal meningitis. Neurobiol. Dis. 28 175–183
11. Bi S, Hong PW, Lee B and Baum LG 2011 Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc. Natl. Acad. Sci. USA 108 10650–10655
12. Burman J and Svenningsson A 2016 Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. J. Neuroimmunol. 292 40–44
13. Chabot S, Kashio Y, Seki M, Shirato Y, Nakamura K, Nishi N, Nakamura T, Matsumoto R, et al. 2002 Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology 12 111–118
14. Chagan-Yasutan H, Ndhlovu LC, Lacuesta TL, Kubo T, Leano PS, Niki T, Oguma S, Morita K, et al. 2013 Galectin-9 plasma levels reflect adverse hematological and immunological features in acute dengue virus infection. J. Clin. Virol. 58 635–640
15. Chou FC, Kuo CC, Wang YL, Lin MH, Linju Yen B, Chang DM and Sytwu HK 2013 Overexpression of galectin-9 in islets prolongs grafts survival via downregulation of Th1 responses. Cell Transplant 22 2135–2145
16. Cirino G, Napoli C, Bucci M and Cicala C 2000 Inflammation-coagulation network: are serine protease receptors the knot? Trends Pharmacol. Sci. 21 170–172
17. Clayton KL, Haaland MS, Douglas-Vail MB, Mujib S, Chew GM, Ndhlovu LC and Ostrowski MA 2014 T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases. J. Immunol. 192 782–791
18. Dai SY, Nakagawa R, Itoh A, Murakami H, Kashio Y, Abe H, Katoh S, Kontani K, et al. 2005 Galectin-9 induces maturation of human monocyte-derived dendritic cells. J. Immunol. 175 2974–2981
19. Danguy A, Camby I and Kiss R 2002 Galectins and cancer. Biochim. Biophys. Acta 1572 285–293
20. de Kivit S, Saeland E, Kraneveld AD, van de Kant HJ, Schouten B, van Esch BC, Knol J, Sprikkelman AB, et al. 2012 Galectin-9 induced by dietary synbiotics is involved in suppression of allergic symptoms in mice and humans. Allergy 67 343–352
21. Dekker RJ, Boon RA, Rondaij MG, Kragt A, Volger OL, Elderkamp YW, Meijers JC, Voorberg J, et al. 2006 KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 107 4354–4363
22. Dumic J, Dabelic S and Flogel M 2006 Galectin-3: an open-ended story. Biochim. Biophys. Acta 1760 616–635
23. Elahi S, Niki T, Hirashima M and Horton H 2012 Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection. Blood. 119 4192–4204
24. Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, et al. 2007 Large-scale mapping of human protein–protein interactions by mass spectrometry. Mol. Syst. Biol. 3 89
25. Fukata Y, Itoh A, Nonaka Y, Ogawa T, Nakamura T, Matsushita O and Nishi N 2014 Direct cytocidal effect of galectin-9 localized on collagen matrices on human immune cell lines. Biochim. Biophys. Acta 1840 1892–1901
26. Fukushima A, Sumi T, Fukuda K, Kumagai N, Nishida T, Akiba H, Okumura K, Yagita H, et al. 2007 Antibodies to T-cell Ig and mucin domain-containing proteins (Tim)-1 and -3 suppress the induction and progression of murine allergic conjunctivitis. Biochem. Biophys. Res. Commun. 353 211–216
27. Gabius HJ 2000 Biological information transfer beyond the genetic code: the sugar code. Naturwissenschaften 87 108–121
28. Gabius HJ, Siebert HC, Andre S, Jimenez-Barbero J and Rudiger H 2004 Chemical biology of the sugar code. Chembiochem. 5 740–764
29. Gooden MJ, Wiersma VR, Samplonius DF, Gerssen J, van Ginkel RJ, Nijman HW, Hirashima M, Niki T, et al. 2013 Galectin-9 activates and expands human T-helper 1 cells. PLoS One 8 e65616
30. Gustavsson E, Sernbo S, Andersson E, Brennan DJ, Dictor M, Jerkeman M, Borrebaeck CAK and Ek S 2010 SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies. Mol. Cancer 9 187
31. Hao H, He M, Li J, Zhou Y, Dang J, Li F, Yang M and Deng D 2015 Upregulation of the Tim-3/Gal-9 pathway and correlation with the development of preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 194 85–91
32. Heusschen R, Griffioen AW and Thijssen VL 2013 Galectin-9 in tumor biology: a jack of multiple trades. Biochim. Biophys. Acta 1836 177–185
33. Heusschen R, Schulkens IA, van Beijnum J, Griffioen AW and Thijssen VL 2014 Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochim. Biophys. Acta 1842 284–292
34. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, et al. 2002 Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim. Biophys. Acta Gen. Subj. 1572 232–254
35. Hirao H, Uchida Y, Kadono K, Tanaka H, Niki T, Yamauchi A, Hata K, Watanabe T, et al. 2015 The protective function of galectin‐9 in liver ischemia and reperfusion injury in mice. Liver Transpl. 21 969–981
36. Hirashima M, Kashio Y, Nishi N, Yamauchi A, Imaizumi T-A, Kageshita T, Saita N and Nakamura T 2004 Galectin-9 in physiological and pathological conditions. Glycoconj. J. 19 593–600
37. Hughes RC 2001 Galectins as modulators of cell adhesion. Biochimie 83 667–676
38. Hughes RC 1999 Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim. Biophys. Acta 1473 172–185
39. Igawa K, Satoh T, Hirashima M and Yokozeki H 2006 Regulatory mechanisms of galectin-9 and eotaxin-3 synthesis in epidermal keratinocytes: possible involvement of galectin-9 in dermal eosinophilia of Th1-polarized skin inflammation. Allergy 61 1385–1391
40. Imaizumi T, Yoshida H, Nishi N, Sashinami H, Nakamura T, Hirashima M, Ohyama C, Itoh K, et al. 2007 Double-stranded RNA induces galectin-9 in vascular endothelial cells: involvement of TLR3, PI3K, and IRF3 pathway. Glycobiology 17 12C–15C
41. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, Seki M, Nishi N, et al. 2005 Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin. Cancer Res. 11 2962–2968
42. Jayaraman P, Sada-Ovalle I, Nishimura T, Anderson AC, Kuchroo VK, Remold HG and Behar SM 2013 IL-1beta promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation. J. Immunol. 190 4196–4204
43. Ji XJ, Ma CJ, Wang JM, Wu XY, Niki T, Hirashima M, Moorman JP and Yao ZQ 2013 HCV-infected hepatocytes drive CD4+ CD25+ Foxp3+ regulatory T-cell development through the Tim-3/Gal-9 pathway. Eur. J. Immunol. 43 458–467
44. Johannes L and Romer W 2010 Shiga toxins--from cell biology to biomedical applications. Nat. Rev. Microbiol. 8 105–116
45. Johswich A, Longuet C, Pawling J, Rahman AA, Ryczko M, Drucker DJ and Dennis JW 2014 N-glycan remodeling on glucagon receptor is an effector of nutrient sensing by the hexosamine biosynthesis pathway. J. Biol. Chem. 289 15927–15941
46. Kadowaki T, Morishita A, Niki T, Hara J, Sato M, Tani J, Miyoshi H, Yoneyama H, et al. 2013 Galectin-9 prolongs the survival of septic mice by expanding Tim-3-expressing natural killer T cells and PDCA-1+ CD11c+ macrophages. Crit. Care 17 R284
47. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, Shoji H, Nakamura T, et al. 2002 Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int. J. Cancer 99 809–816
48. Kanzaki M, Wada J, Sugiyama K, Nakatsuka A, Teshigawara S, Murakami K, Inoue K, Terami T, et al. 2012 Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Endocrinology 153 612–620
49. Kasai K and Hirabayashi J 1996 Galectins: a family of animal lectins that decipher glycocodes. J. Biochem. 119 1–8
50. Kasamatsu A, Uzawa K, Shimada K, Shiiba M, Otsuka Y, Seki N, Abiko Y and Tanzawa H 2005a Elevation of galectin-9 as an inflammatory response in the periodontal ligament cells exposed to Porphylomonas gingivalis lipopolysaccharide in vitro and in vivo. Int. J. Biochem. Cell Biol. 37 397–408
51. Kasamatsu A, Uzawa K, Nakashima D, Koike H, Shiiba M, Bukawa H, Yokoe H and Tanzawa H 2005b Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int. J. Mol. Med. 16 269–273
52. Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, Nakamura T and Hirashima M 2003 Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J. Immunol. 170 3631–3636
53. Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai SY, Shinonaga R, Niki T, Nishi N, et al. 2007 Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am. J. Respir. Crit. Care Med. 176 27–35
54. Keryer-Bibens C, Pioche-Durieu C, Villemant C, Souquere S, Nishi N, Hirashima M, Middeldorp J and Busson P 2006 Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 6 283
55. Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S-i, Niiro H, Yurino A, et al. 2015 A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell 17 341–352
56. Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le Moulec S, Guigay J, et al. 2009 Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood. 113 1957–1966
57. Kobayashi K, Morishita A, Iwama H, Fujita K, Okura R, Fujihara S, Yamashita T, Fujimori T, et al. 2015 Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. Oncol. Rep. 34 1761–1770
58. Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, Adachi S, Takagi T, et al. 2010 Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia 24 843–850
59. Komita H, Koido S, Hayashi K, Kan S, Ito M, Kamata Y, Suzuki M and Homma S 2015 Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors. Oncol. Rep. 34 2099–2105
60. Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, Horiike S, Kimura S, et al. 2010 Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol. Cancer Res. 8 994–1001
61. Kurose Y, Wada J, Kanzaki M, Teshigawara S, Nakatsuka A, Murakami K, Inoue K, Terami T, et al. 2013 Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease. BMC Nephrol. 14 23
62. Lahm H, Andre S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E and Gabius HJ 2001 Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J. Cancer Res. Clin. Oncol. 127 375–386
63. Lahm H, Hoeflich A, Andre S, Sordat B, Kaltner H, Wolf E and Gabius HJ 2000 Gene expression of galectin-9/ecalectin, a potent eosinophil chemoattractant, and/or the insertional isoform in human colorectal carcinoma cell lines and detection of frame-shift mutations for protein sequence truncations in the second functional lectin domain. Int. J. Oncol. 17 519–524
64. Leal-Pinto E, Tao W, Rappaport J, Richardson M, Knorr BA and Abramson RG 1997 Molecular cloning and functional reconstitution of a urate transporter/channel. J. Biol. Chem. 272 617–625
65. Leber MF and Efferth T 2009 Molecular principles of cancer invasion and metastasis (review). Int. J. Oncol. 34 881–895
66. Leffler H, Carlsson S, Hedlund M, Qian Y and Poirier F 2004 Introduction to galectins. Glycoconj. J. 19 433–440
67. Li YH, Zhou WH, Tao Y, Wang SC, Jiang YL, Zhang D, Piao HL, Fu Q, et al. 2016 The Galectin-9/Tim-3 pathway is involved in the regulation of NK cell function at the maternal-fetal interface in early pregnancy. Cell. Mol. Immunol. 13 73–81
68. Liang M, Ueno M, Oomizu S, Arikawa T, Shinonaga R, Zhang S, Yamauchi A and Hirashima M 2008 Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 134 899–907
69. Liberal R, Grant CR, Holder BS, Ma Y, Mieli-Vergani G, Vergani D and Longhi MS 2012 The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. Hepatology 56 677–686
70. Liu Z, Han H, He X, Li S, Wu C, Yu C and Wang S 2016 Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma. Oncol. Lett. 11 1829–1834
71. Lv K, Zhang Y, Zhang M, Zhong M and Suo Q 2012 Galectin-9 ameliorates Con A-induced hepatitis by inducing CD4(+)CD25(low/int) effector T-Cell apoptosis and increasing regulatory T cell number. PLoS One 7 e48379
72. Ma CJ, Li GY, Cheng YQ, Wang JM, Ying RS, Shi L, Wu XY, Niki T, et al. 2013 Cis association of galectin-9 with Tim-3 differentially regulates IL-12/IL-23 expressions in monocytes via TLR signaling. PLoS One 8 e72488
73. Madireddi S, Eun SY, Lee SW, Nemcovicova I, Mehta AK, Zajonc DM, Nishi N, Niki T, et al. 2014 Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J. Exp. Med. 211 1433–1448
74. Matsumoto R 1998 Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J. Biol. Chem. 273 16976–16984
75. Matsumoto R, Hirashima M, Kita H and Gleich GJ 2002 Biological activities of ecalectin: a novel eosinophil-activating factor. J. Immunol. 168 1961–1967
76. Matsushita N, Nishi N, Seki M, Matsumoto R, Kuwabara I, Liu FT, Hata Y, Nakamura T, et al. 2000 Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. J. Biol. Chem. 275 8355–8360
77. Matsuura A, Tsukada J, Mizobe T, Higashi T, Mouri F, Tanikawa R, Yamauchi A, Hirashima M, et al. 2009 Intracellular galectin-9 activates inflammatory cytokines in monocytes. Genes Cells 14 511–521
78. Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, Mcwilliams R, Randall JA, Mcmahan R, et al. 2010 A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One 5 e9504
79. Mishra R, Grzybek M, Niki T, Hirashima M and Simons K 2010 Galectin-9 trafficking regulates apical-basal polarity in Madin-Darby canine kidney epithelial cells. Proc. Natl. Acad. Sci. USA 107 17633–17638
80. Miyanishi N, Nishi N, Abe H, Kashio Y, Shinonaga R, Nakakita S, Sumiyoshi W, Yamauchi A, et al. 2007 Carbohydrate-recognition domains of galectin-9 are involved in intermolecular interaction with galectin-9 itself and other members of the galectin family. Glycobiology 17 423–432
81. Moritoki M, Kadowaki T, Niki T, Nakano D, Soma G, Mori H, Kobara H, Masaki T, et al. 2013 Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3. PLoS One. 8, e60807
82. Munitz A and Levi-Schaffer F 2004 Eosinophils: ‘new’ roles for ‘old’ cells. Allergy 59 268–275
83. Murphy PV, Andre S and Gabius HJ 2013 The third dimension of reading the sugar code by lectins: design of glycoclusters with cyclic scaffolds as tools with the aim to define correlations between spatial presentation and activity. Molecules 18 4026–4053
84. Nagae M, Nishi N, Murata T, Usui T, Nakamura T, Wakatsuki S and Kato R 2006 Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition. J. Biol. Chem. 281 35884–35893
85. Nagae M, Nishi N, Murata T, Usui T, Nakamura T, Wakatsuki S and Kato R 2009 Structural analysis of the recognition mechanism of poly-N-acetyllactosamine by the human galectin-9 N-terminal carbohydrate recognition domain. Glycobiology 19 112–117
86. Nagae M, Nishi N, Nakamura-Tsuruta S, Hirabayashi J, Wakatsuki S and Kato R 2008 Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue. J. Mol. Biol. 375 119–135
87. Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, Watanabe K, Niki T, et al. 2008 Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J. Immunol. 181 7660–7669
88. Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y, Rosenberg W, Dusheiko G, et al. 2012 Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One 7 e47648
89. Niki T, Tsutsui S, Hirose S, Aradono S, Sugimoto Y, Takeshita K, Nishi N and Hirashima M 2009 Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. J. Biol. Chem. 284 32344–32352
90. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, Shoji H and Nakamura T 2005 Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett. 579 2058–2064
91. Nishi N, Itoh A, Shoji H, Miyanaka H and Nakamura T 2006 Galectin-8 and galectin-9 are novel substrates for thrombin. Glycobiology 16 15C–20C
92. Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, Takeshita K, Niki T, Tominaga A, et al. 2008 Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 18 735–744
93. Nonaka Y, Ogawa T, Oomizu S, Nakakita S, Nishi N, Kamitori S, Hirashima M and Nakamura T 2013 Self-association of the galectin-9 C-terminal domain via the opposite surface of the sugar-binding site. J. Biochem. 153 463–471
94. Obinata H and Hla T 2012 Sphingosine 1-phosphate in coagulation and inflammation. Semin. Immunopathol. 34 73–91
95. Ohtsubo K, Takamatsu S, Minowa MT, Yoshida A, Takeuchi M and Marth JD 2005 Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell 123 1307–1321
96. Park WS, Jung W-K, Park SK, Heo KW, Kang M-S, Choi YH, Kim G-Y, Park S-G, et al. 2011 Expression of galectin-9 by IFN-γ stimulated human nasal polyp fibroblasts through MAPK, PI3K, and JAK/STAT signaling pathways. Biochem. Biophys. Res. Commun. 411 259–264
97. Reddy PBJ, Schreiber TH, Rajasagi NK, Suryawanshi A, Mulik S, Veiga-Parga T, Niki T, Hirashima M, et al. 2012 TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions. J. Virol. 86 10606–10620
98. Pelletier I, Hashidate T, Urashima T, Nishi N, Nakamura T, Futai M, Arata Y, Kasai K, et al. 2003 Specific recognition of Leishmania major poly-beta-galactosyl epitopes by galectin-9: possible implication of galectin-9 in interaction between L. major and host cells. J. Biol. Chem. 278 22223–22230
99. Pena C, Mirandola L, Figueroa JA, Hosiriluck N, Suvorava N, Trotter K, Reidy A, Rakhshanda R, et al. 2014 Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness. Ann. Transl. Med. 2 87
100. Pioche-Durieu C, Keryer C, Souquere S, Bosq J, Faigle W, Loew D, Hirashima M, Nishi N, et al. 2005 In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. J. Virol. 79 13326–13337
101. Qiao X, Jiang K, Nie J, Fan K, Zheng Z, Wang J and Li J 2014 Increased expression of Tim-3 and its ligand Galectin-9 in rat allografts during acute rejection episodes. Biochem. Biophys. Res. Commun. 445 542–548
102. Rajendran L, Knolker HJ and Simons K 2010 Subcellular targeting strategies for drug design and delivery. Nat. Rev. Drug Discov. 9 29–42
103. Reddy PB, Sehrawat S, Suryawanshi A, Rajasagi NK, Mulik S, Hirashima M and Rouse BT 2011 Influence of galectin-9/Tim-3 interaction on herpes simplex virus-1 latency. J. Immunol. 187 5745–5755
104. Rhodes DH, Pini M, Castellanos KJ, Montero-Melendez T, Cooper D, Perretti M and Fantuzzi G 2013 Adipose tissue-specific modulation of galectin expression in lean and obese mice: evidence for regulatory function. Obesity (Silver Spring) 21 310–319
105. Sada-Ovalle I, Chavez-Galan L, Torre-Bouscoulet L, Nava-Gamino L, Barrera L, Jayaraman P, Torres-Rojas M, Salazar-Lezama MA, et al. 2012 The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis. J. Immunol. 189 5896–5902
106. Saitoh H, Ashino Y, Chagan-Yasutan H, Niki T, Hirashima M and Hattori T 2012 Rapid decrease of plasma galectin-9 levels in patients with acute HIV infection after therapy. Tohoku J. Exp. Med. 228 157–161
107. Sakai K, Kawata E, Ashihara E, Nakagawa Y, Yamauchi A, Yao H, Nagao R, Tanaka R, et al. 2011 Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. Eur. J. Immunol. 41 67–75
108. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK and Anderson AC 2010 Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207 2187–2194
109. Samoszuk M 1997 Eosinophils and human cancer. Histol Histopathol 12(3) 807–812
110. Sanchez-Cuellar S, de la Fuente H, Cruz-Adalia A, Lamana A, Cibrian D, Giron RM, Vara A, Sanchez-Madrid F, et al. 2012 Reduced expression of galectin-1 and galectin-9 by leucocytes in asthma patients. Clin. Exp. Immunol. 170 365–374
111. Sato M, Nishi N, Shoji H, Seki M, Hashidate T, Hirabayashi J, Kasai K-i, Hata Y, et al. 2002 Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. Glycobiology 12 191–197
112. Schlotzer-Schrehardt U, Andre S, Janko C, Kaltner H, Kopitz J, Gabius HJ and Herrmann M 2012 Adhesion/growth-regulatory galectins in the human eye: localization profiles and tissue reactivities as a standard to detect disease-associated alterations. Graefes Arch. Clin. Exp. Ophthalmol. 250 1169–1180
113. Seki M, Sakata KM, Oomizu S, Arikawa T, Sakata A, Ueno M, Nobumoto A, Niki T, et al. 2007 Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum. 56 3968–3976
114. Sharma S, Sundararajan A, Suryawanshi A, Kumar N, Veiga-Parga T, Kuchroo VK, Thomas PG, Sangster MY, et al. 2011 T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc. Natl. Acad. Sci. USA 108 19001–19006
115. Shimizu Y, Kabir-Salmani M, Azadbakht M, Sugihara K, Sakai K and Iwashita M 2008 Expression and localization of galectin-9 in the human uterodome. Endocr. J. 55 879–887
116. Shimmura-Tomita M, Wang M, Taniguchi H, Akiba H, Yagita H and Hori J 2013 Galectin-9-mediated protection from allo-specific T cells as a mechanism of immune privilege of corneal allografts. PLoS One 8 e63620
117. Solís D, Maté MJ, Lohr M, Ribeiro JP, López-Merino L, André S, Buzamet E, Javier Cañada F, et al. 2010 N-domain of human adhesion/growth-regulatory galectin-9: preference for distinct conformers and non-sialylated N-glycans and detection of ligand-induced structural changes in crystal and solution. Int. J. Biochem. Cell Biol. 42 1019–1029
118. Spitzenberger F, Graessler J and Schroeder HE 2001 Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. Biochimie. 83 851–862
119. Stancic M, van Horssen J, Thijssen VL, Gabius HJ, van der Valk P, Hoekstra D and Baron W 2011 Increased expression of distinct galectins in multiple sclerosis lesions. Neuropathol. Appl. Neurobiol. 37 654–671
120. Steelman AJ, Smith R, Welsh CJ and Li J 2013 Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis. J. Biol. Chem. 288 23776–23787
121. Straube T, von Mach T, Honig E, Greb C, Schneider D and Jacob R 2013 pH-dependent recycling of galectin-3 at the apical membrane of epithelial cells. Traffic 14 1014–1027
122. Strukova SM 2001 Thrombin as a regulator of inflammation and reparative processes in tissues. Biochemistry (Mosc). 66 8–18
123. Sun J, Yang M, Ban Y, Gao W, Song B, Wang Y, Zhang Y, Shao Q, et al. 2016 Tim-3 is upregulated in NK cells during early pregnancy and inhibits NK cytotoxicity toward trophoblast in galectin-9 dependent pathway. PLoS One 11 e0147186
124. Tadokoro T, Morishita A, Fujihara S, Iwama H, Niki T, Fujita K, Akashi E, Mimura S, et al. 2016 Galectin-9: an anticancer molecule for gallbladder carcinoma. Int. J. Oncol. 48 1165–1174
125. Takano J, Morishita A, Fujihara S, Iwama H, Kokado F, Fujikawa K, Fujita K, Chiyo T, et al. 2016 Galectin-9 suppresses the proliferation of gastric cancer cells in vitro. Oncol. Rep. 35 851–860
126. Tang ZH, Liang S, Potter J, Jiang X, Mao HQ and Li Z 2013 Tim-3/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J. Immunol. 190 1788–1796
127. Tanikawa R, Tanikawa T, Hirashima M, Yamauchi A and Tanaka Y 2010 Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. Biochem. Biophys. Res. Commun. 394 317–322
128. Tanikawa R, Tanikawa T, Okada Y, Nakano K, Hirashima M, Yamauchi A, Hosokawa R and Tanaka Y 2008 Interaction of galectin-9 with lipid rafts induces osteoblast proliferation through the c-Src/ERK signaling pathway. J. Bone Miner. Res. 23 278–286
129. Tao W 1997 Molecular cloning and functional reconstitution of a urate transporter/channel. J. Biol. Chem. 272 617–625
130. Tao YF, Lin F, Yan XY, Gao XG, Teng F, Fu ZR and Wang ZX 2015 Galectin-9 in combination with EX-527 prolongs the survival of cardiac allografts in mice after cardiac transplantation. Transplant. Proc. 47 2003–2009
131. Than NG, Romero R, Goodman M, Weckle A, Xing J, Dong Z, Xu Y, Tarquini F, et al. 2009 A primate subfamily of galectins expressed at the maternal–fetal interface that promote immune cell death. Proc. Natl. Acad. Sci. 106 9731–9736
132. Thijssen VL, Heusschen R, Caers J and Griffioen AW 2015 Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim. Biophys. Acta. 1855 235–247
133. Thijssen VL, Hulsmans S and Griffioen AW 2008 The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am. J. Pathol. 172 545–553
134. Martin TA, Ye L, Sanders AJ, Lane J and Jiang WG 2013 Cancer invasion and metastasis: molecular and cellular perspective. In: Madame Curie Bioscience database [Internet] (Austin (TX): Landes Bioscience)
135. Tsuchiyama Y, Wada J, Zhang H, Morita Y, Hiragushi K, Hida K, Shikata K, Yamamura M, et al. 2000 Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats. Kidney Int. 58 1941–1952
136. Tureci O, Schmitt H, Fadle N, Pfreundschuh M and Sahin U 1997 Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J. Biol. Chem. 272 6416–6422
137. Ungerer C, Quade-Lyssy P, Radeke HH, Henschler R, Konigs C, Kohl U, Seifried E and Schuttrumpf J 2014 Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations. Stem Cells Dev. 23 755–766
138. van den Brule F, Califice S and Castronovo V 2004 Expression of galectins in cancer: a critical review. Glycoconj. J. 19 537–542
139. Vasta GR, Ahmed H, Nita-Lazar M, Banerjee A, Pasek M, Shridhar S, Guha P and Fernández-Robledo JA 2012 Galectins as self/non-self recognition receptors in innate and adaptive immunity: an unresolved paradox. Front. Immunol. 3 199
140. Vega-Carrascal I, Bergin DA, Mcelvaney OJ, McCarthy C, Banville N, Pohl K, Hirashima M, Kuchroo VK, et al. 2014 Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung. J. Immunol. 192 2418–2431
141. Vega-Carrascal I, Reeves EP, Niki T, Arikawa T, Mcnally P, O'Neill SJ, Hirashima M and Mcelvaney NG 2011 Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways. J. Immunol. 186 2897–2909
142. Villalobo A and Gabius H 1998 Signaling pathways for transduction of the initial message of the glycocode into cellular responses. Acta Anat. (Basel). 161 110–129
143. Vladoiu MC, Labrie M and St-Pierre Y 2014 Intracellular galectins in cancer cells: potential new targets for therapy (Review). Int. J. Oncol. 44 1001–1014
144. von Mach T, Carlsson MC, Straube T, Nilsson U, Leffler H and Jacob R 2014 Ligand binding and complex formation of galectin-3 is modulated by pH variations. Biochem. J. 457 107–115
145. Wada J, Ota K, Kumar A, Wallner EI and Kanwar YS 1997 Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J. Clin. Investig. 99 2452–2461
146. Wang F, He W, Zhou H, Yuan J, Wu K, Xu L and Chen ZK 2007 The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell. Immunol. 250 68–74
147. Wang F, Xu J, Liao Y, Wang Y, Liu C, Zhu X, Chen ZK and Sun Z 2011 Tim-3 ligand galectin-9 reduces IL-17 level and accelerates Klebsiella pneumoniae infection. Cell. Immunol. 269 22–28
148. Wedemeyer J and Vosskuhl K 2008 Role of gastrointestinal eosinophils in inflammatory bowel disease and intestinal tumours. Best Pract. Res. Clin. Gastroenterol. 22 537–549
149. Weigle B, Ebner R, Temme A, Schwind S, Schmitz M, Kiessling A, Rieger MA, Schackert G, et al. 2005 Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. Oncol. Rep. 13 139–144
150. Wiersma VR, de Bruyn M, Helfrich W and Bremer E 2013 Therapeutic potential of Galectin-9 in human disease. Med. Res. Rev. 33 E102–E126
151. Wiersma VR, de Bruyn M, van Ginkel RJ, Sigar E, Hirashima M, Niki T, Nishi N, Samplonius DF, et al. 2012 The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells. J. Invest. Dermatol. 132 2302–2305
152. Wu C, Thalhamer T, Franca RF, Xiao S, Wang C, Hotta C, Zhu C, Hirashima M, et al. 2014 Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity. 41 270–282
153. Yang Q, Jiang W, Zhuang C, Geng Z, Hou C, Huang D, Hu L and Wang X 2015 microRNA-22 downregulation of galectin-9 influences lymphocyte apoptosis and tumor cell proliferation in liver cancer. Oncol. Rep. 34 1771–1778
154. Yang RY, Rabinovich GA and Liu FT 2008 Galectins: structure, function and therapeutic potential. Expert Rev. Mol. Med. 10 e17
155. Yoshida H, Teraoka M, Nishi N, Nakakita S, Nakamura T, Hirashima M and Kamitori S 2010 X-ray structures of human galectin-9 C-terminal domain in complexes with a biantennary oligosaccharide and sialyllactose. J. Biol. Chem. 285 36969–36976
156. Zhang F, Zheng M, Qu Y, Li J, Ji J, Feng B, Lu A, Li J, et al. 2009 Different roles of galectin-9 isoforms in modulating E-selectin expression and adhesion function in LoVo colon carcinoma cells. Mol. Biol. Rep. 36 823–830
157. Zhang Q, Luan H, Wang L, He F, Zhou H, Xu X, Li X, Xu Q, et al. 2014a Galectin-9 ameliorates anti-GBM glomerulonephritis by inhibiting Th1 and Th17 immune responses in mice. Am. J. Physiol. Renal Physiol. 306 F822–F832
158. Zhang XM and Shan NN 2014 The role of T cell immunoglobulin and mucin domain-3 in immune thrombocytopenia. Scand. J. Immunol. 79 231–236
159. Zhang Y, Jiang L, Zhang M and Lv K 2014b Galectin-9 induced myeloid suppressor cells expand regulatory T cells in an IL-10-dependent manner in CVB3-induced acute myocarditis. Int. J. Mol. Sci. 15 3356–3372
160. Zhang ZY, Dong JH, Chen YW, Wang XQ, Li CH, Wang J, Wang GQ, Li HL, et al. 2012 Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 13 2503–2509
161. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, et al. 2005 The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6 1245–1252